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INTRODUCTION
Pancreatitis constitutes a prevailing clinical condition 
characterized by inflammatory process in the pancre-
as affecting both its exocrine and endocrine function. 
The disease can be classified according to its duration. 
Based on this, acute pancreatitis represents a mild, 
self-limited condition accompanied by elevated se-
rum pancreatic enzymes levels. Chronic pancreatitis 
(CP) is the progressive and irreversible destruction of 
the pancreas which often (if not always) appears as 
the result of clinical or subclinical episodes of acute 
pancreatitis. In this sense, one can consider these two 
clinical conditions as parts of the same entity in which 
the transition from the acute to the chronic state can 
be subtle or even not perceived1. The main histologi-
cal findings in CP are the destruction of the pancreatic 
parenchymal and ductal anatomy, fibrosis, loss of aci-
nar and islet cells and the infiltration of inflammatory 
cells in the gland. One of the predominant symptoms 
of CP is pain which is constant or recurrent intense 
abdominal (often radiating to the back) present in 80-
90% of patients2.
Pain compromises a very common symptom en-
countered in everyday clinical practice. Defining pain 
is quite difficult since it is perceived more as a person-
al experience. In 1979 the International Association 
for the Study of Pain (IASP) established pain as an 
unpleasant sensory and emotional experience in rela-
tion with a real or potential tissue destruction or de-
scribed as such 3. Pain can be classified as normal re-
ferring to the term noxious. This is the temporal sense 
triggered by a stimulus of such intensity that causes 
tissue damage or a small patulous trauma without ex-
tensive inflammation or nervous system damage. This 
kind of pain can be caused by a thermical, chemical 
or mechanical stimulus and it can be considered as a 
protective mechanism against harmful factors. Patho-
logical pain is the result of inflammatory reaction pro-
voked by tissue destruction or nervous system harm. 
Its distinguishing feature is the incongruity between 
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stimulus-reaction in the sense that the stimulus is not 
adequate to cause pain sensation of such intensity. 
This is due to the fact that there is a change in the 
nociceptive system of pain. This results in central hy-
persensitivity which does not allow for the incoming 
sensory information to be evaluated correctly4. Pain 
can be caused even in the absence of a stimulus and 
it may not be restricted in the trauma area. Pain also 
is sorted as acute or chronic and somatic, visceral or 
neuropathic. Being a multifactory and complex entity, 
pain consists of three elements. The sensory-discrim-
inative, capable of localizing pain area and assessing 
its intensity. The affective- motivational quantifies 
how unpleasant pain is and provokes feelings like 
fear and distress. The cognitive-evaluative component 
takes part in memory of the experience and evaluates 
this5.
The pancreas has a complicated innervation, the 
extrinsic and the intrinsic one. Extrinsic innervation 
consists of both afferent and efferent nerve fibers 
supplied by the vagus nerve (parasympathetic) and 
splachnic nerves (sympathetic).Visceral information 
is transferred to the central nervous system (CNS) ei-
ther by the vagus nerve to the brainstem or splachnic 
nerves to the spinal cord. These two types of nerves 
are considered the ones for signaling pancreatic pain 
stimuli6. It is commonly accepted that nociceptive in-
formation is mainly transmitted via splanchic nerves. 
The cell bodies for the axons can be found in the tho-
racic dorsal root (Level T5-T10 for splachnic nerves) 
and in nodose ganglia (for vagus nerve). Intrinsic in-
nervation consists of intrapancreatic ganglia and nerve 
fibers from duodenum’s enteric neurons, the so-called 
enteropancreatic innervation7. As far as nociceptive 
input is concerned, it is regarded that dermatomes 
between somatic and visceral neurons can converge. 
Dermatome T10 is thought to converge with pancre-
atic viscerotomes8.
Considering the sensory pathway of pain, how 
pain is transmitted from the periphery to brain cen-
ters and how it is perceived and further analyzed, one 
can say that a number of different agents is involved. 
The pain stimulus is carried from the periphery to the 
center mainly via the myelinated Αδ and the unmy-
elinated C sensory nerve fibers. Αδ nerve fibers are 
thought to transmit acute pain whereas C fibers are 
related to demersal, dull pain6. Through these fibers, 
stimulation reaches the first-order neurons, the cells 
of dorsal ganglions. Spinal nerves consist of somato-
motor efferent fibers, somato-sensory afferent fibers, 
viscero-motor efferent fibers and viscerosensory af-
ferent nerve fibers. The pain stimulus is then trans-
mitted to the second-order neurons, the cells of the 
dorsal horn nuclei and the dorsal substantia gelatinosa 
cells located in dorsal horn. Excitation is carried to the 
second-order neurons via the posterior roots of spinal 
nerves and the dorsolateral fasciculus respectively. 
The stimulus ends up in the third-order neurons, the 
cells of the thalamus postero-external ventral nucle-
us via the lateral spinothalamic fasciculus. An acute, 
sting pain related stimulus is transmitted to these neu-
rons. Finally, pain excitation will reach the cortex of 
the central posterior gyrus. In case the stimulus refers 
to burning pain, it is transferred to the reticular forma-
tion’s nuclei cells cited in the cerebral brainstem via 
the spinothalamic lateral fasciculus. From that point, 
excitation will alert and inform the CNS of a potential 
injury exemplified through pain perception. However, 
the final perception of pain appears to be the result of 
both facilitatory and inhibitory mechanisms. Inhibi-
tory descending pathways are responsible for prevent-
ing pain signals from reaching the CNS and are found 
in the periaqueductal grey, the locus coeruleus and the 
dorsal reticular nucleus in the medulla9,6. Thus a prop-
er answer to the painful stimulus can be expressed via 
the motor system’s efferent nerves and the autonomic 
nervous system9.
Clarifying the etiology of pain in CP seems a chal-
lenge, since a number of different theories has been 
proposed. Extrapancreatic causes concern bile duct 
and duodenal stenosis due to fibrosis and inflamma-
tion. Pancreatic causes refer to increased intrapancre-
atic pressure mechanisms, hypercholecystokininemia, 
the compartment syndrome, pancreatic fibrogenesis, 
oxidative stress, gene mutations which contribute to 
the inflammatory process and complications from the 
pancreas, like pseudocysts and masses. 
Bile duct and duodenal stenosis
It is accepted that CP causes intense fibrosis, pancreat-
ic and peripancreatic tissue inflammation in its course. 
Taken together fibrosis and inflammation can provoke 
stenosis to nearby organs (bile duct or duodenum) 
by the formation of strictures. Stenosis developed as 
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a complication of CP has been seen as the source of 
pain in the disease10. There is evidence that pain can 
be alleviated by biliary drainage methods applied to 
common bile duct stenosis. On the other hand, bili-
ary stenosis and its role in the induction of pain have 
been highly questioned by other authors11,3. Stenosis 
has also been regarded as a complication of a patho-
logical entity called “groove pancreatitis”. The term 
was firstly introduced by Stolte et al12 to describe a 
condition found in 19.5% of 600 CP patients. Its main 
characteristic is a scar or fibrous plate formed between 
the pancreatic head and the duodenum’s wall. This 
plate can result in complications like a disturbance in 
the duodenum’s motility and a duodenal and/or com-
mon bile duct stenosis. Nerves and ganglia located 
between the pancreatic head and the duodenum are 
compressed by the fibrous plate and this can trigger 
pain in CP patients13.
Increased intrapancreatic pressure mechanisms
Another hypothesis of CP pain generation concerns 
pancreatic causative mechanisms. Increased intrapan-
creatic pressure is the pathological entity referring 
to both ductal and pancreatic interstitial hyperten-
sion. This condition of pressure is thought to cause 
a compartment syndrome which inevitably leads to 
pain induction14. In the ductal system normal pres-
sure ranges from 7 to 15 mmHg. However in the case 
of CP patients, ductal hypertension has been found 
20mmHg with a maximum of 80 mmHg15,16. This 
ductal hypertension theory is based on the assumption 
that the increased secretion of pancreatic juice along 
with an obstruction because of strictures or calculi/
stones leads to an elevated pressure. This CP genera-
tion pain mechanism has been supported by many 
researchers in the past17,18.Another study19, also es-
tablished a relation between intrapancreatic pressure 
and the intensity of abdominal pain. However, there 
have been studies that demonstrate the opposite case, 
namely that pancreatic duct pressure is not the main 
source of pain. It was found that CP patients still ex-
perience pain after pancreatic duct drainage methods 
have been applied. Pain was perceived as being the 
same like before drainage or in some other cases long-
term pain relief was not achieved. Pain was recorded 
to reoccur in about 40% of CP patients undergoing a 
drainage procedure20. At the same time, another study 
by Vestergaard et al21 documented no relation between 
manometric findings and the severity of CP.
Pancreatic parenchymal tissue hypertension has 
also been proposed as a major factor in CP pain gener-
ation and its intensity22. The chronically inflamed pan-
creas causes an extended fibrosis which in turn does 
not allow the gland to expand and absorb the already 
created pressure by the increased ductal volume. In-
creased parenchymal pressure has been observed in 
CP patients up to 30 mm Hg when the average normal 
pressure in the gland is 7 mmHg4. A rare case has also 
been documented23 in which parenchymal pressure 
was up to 662 mm Hg in an alcoholic CP patient. It 
has also been found that by applying ductal decom-
pression and surgical incision of the gland, pancreatic 
pressure decreases or even returns to normal levels24. 
In case parenchymal tissue pressure increases again 
postoperatively, then pain can reoccur. 
Hypercholecystokininemia
The elevated pressure is also created by the increased 
stimulation and exocrine secretion because of the hy-
percholecystokininemia found in CP. Cholecystoki-
nine (CCK) is thought to generate pain by stimulat-
ing pancreatic juice secretion which contributes to the 
glandular hypertension and ischemia. Elevated CCK 
levels have been documented in some early stage CP 
patients compared to controls.25 Moreover, it has been 
speculated that increased CCK levels induce pancre-
atic pain by acting directly on the CNS, since CCK 
receptors exist in the vomiting center. However, this 
center lacks a blood-brain barrier, so its neurons come 
in contact with CCK in blood and a stimulation of 
pain is achieved26. On the contrary, another study25 ex-
emplifies that there is no connection between exocrine 
secretion of the gland and increased pain levels in CP. 
The validity of the increased pressure theory in CP 
pain induction was also questioned in another study27 
showing that octreotide used for pancreatic secretion 
inhibition did not manage to reduce the CP pain in-
tensity. 
The compartment syndrome
An additional CP pain hypothesis suggests that the 
compartment syndrome resulting from pancreatic 
hypertension plays a vital role. In a feline model of 
chronic pancreatitis28, it was demonstrated that the 
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increased interstitial pressure can cause a blood flow 
reduction. This leads to the gland’s ischemia which at 
least in part has been regarded the source of pain in CP 
as it is a well known stimulus of pain28.
Pancreatic fibrogenesis
One of the main histological findings in CP is the 
development of fibrosis intralobular and perilobular. 
Fibrosis implies the accumulation of fibroblasts and 
collagen which replace exocrine parenchyma. Extend-
ed fibrogenesis with accumulation of extracellular 
matrix can lead to irreversible scarring. Even though 
its pathophysiology still remains unclear, it has been 
suggested that glandular fibrosis provokes an intra-
ductal hypertension and thereby a chronic pain situ-
ation29. Pancreatic fibrosis and collagen synthesis is 
mainly mediated by the pancreatic stellate cells when 
activated. There is evidence that they are activated in 
an early stage of CP after the gland’s injury by alco-
hol consumption. Thus, they produce cytokines and 
chemokines, contributing to fibrogenesis, pancreatic 
tissue ischemia and pain30. Nevertheless, recent stud-
ies emphasize the fact that there does not exist a link 
between fibrogenesis and intensity of pain thus sug-
gesting other, more significant pain generation mecha-
nisms in CP31.
Oxidative stress
The role of oxidative stress has also been implied as a 
possible mediator in CP pain mechanism. More spe-
cifically, it has been suggested that oxygen-derived 
free radicals are involved in the pancreatic inflamma-
tory process as they are cytotoxic agents32, released 
from inflammatory cells when there is an oxidative 
burst. Oxidative stress promotes cell or tissue injury 
directly or indirectly by altering signal pathways or 
provoking inflammation, ischemia or acidosis33. 
Gene mutations
More recently, it has been implied that gene mutations 
can be responsible, at least in part, for the pathogene-
sis of CP pain, especially the hereditary and idiopathic 
CP and recurrent acute pancreatitis pain34. These con-
cern the gene encoding the cationic trypsinogen and 
the gene for the pancreatic secretory trypsin inhibitor. 
At cellular level they are thought to be responsible for 
recurrent episodes of inflammation and pain induc-
tion.
Pancreatic complications
Complications from the pancreas have also been 
thought as the origin of pain in CP. Pseudocysts can 
be responsible for pain especially when they rapidly 
grow in size and compress adjacent organs. In CP, 
they tend to disappear either automatically or with 
octreotide treatment thus ameliorating the pain sensa-
tion35. Pseudocysts are usually considered the result of 
acute exacerbations of CP. In this perspective, acute 
exacerbations can lead to an intense pancreatic and 
peripancreatic tissue inflammation involving noxious 
agents and inflammatory cell infiltration which inevi-
tably aggravates pain intensity. Recurrent attacks of 
acute inflammation seem to promote a cascade of ac-
tivated enzymes and other substances causing thus a 
prolonged pancreatic injury and pain intensification. 
In some cases, an inflammatory pancreatic mass can 
be developed, mainly in the head of the pancreas. In 
such a case, this mass is thought to induce or aggra-
vate CP pain, as it can compress pancreatic or peri-
pancreatic nerves and obstruct the common bile duct 
or the pancreatic duct. .In some other cases, pain is 
the result of CP complications, like a superimposed 
carcinoma, a relevant pathological condition (mainly 
gastroparesis) or an irrelevant coexisting entity3.
So far pain in CP has traditionally been classified 
as inflammatory in nature. However, a new insight 
into its pathogenesis has been offered by the concept 
of the neuropathic pain syndrome in CP. According 
to this, it has been speculated that pain in CP has a 
neuropathic component closely linked to the inflam-
mation process5. Neuropathic pain is defined as “pain 
arising as a direct consequence of a lesion or disease 
affecting the somato-sensory system”36. Most recently 
Demir et al37 characterized CP pain as of mixed-type 
with a mainly neuropathic basis. These researchers 
proposed that pain mechanisms can be classified as 
central or peripheral based on their location and noci-
ceptive or neuropathic according to whether there is a 
stimulation of intact or damaged nerve fibers. In their 
study, CP underlying pain mechanisms were divided 
into the following categories:
Peripheral intrapancreatic nociceptive mecha-
nisms, including hypertension, agents, receptors and 
neurotrophic factors.
Peripheral extrapancreatic nociceptive mecha-
nisms, that is DRG neuronal sensitization.
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Peripheral neuropathic mechanisms: pancre-
atic neuropathy referring to eosinophils infiltration, 
changes in intrapancreatic nerves, neural remodeling 
and chemokines.
Central (spinal) neuropathy, that is spinal neurons’ 
excitability.
Central (cerebral) neuroplasticity involving in-
creased cerebral surface activity and altered brain po-
tentials.
Peripheral intrapancreatic nociceptive mechanisms
Peripheral intrapancreatic nociception refers to stimu-
lation of pain receptors, neurons located in the gland. 
An increased presence of nociceptive signals in the 
periphery (pancreas) is associated with pain genera-
tion in CP. A number of various substances has been 
held responsible for stimulating pancreatic nocicep-
tion via acting upon C or Αδ nerve fibers. In the past, 
it was suggested that hypertension, both ductal and 
panrechymal and toxic agents, like alcohol were the 
main factors in exciting nociceptive nerve fibers29. 
However, later it was found that even in the absence 
of these factors CP patients still experienced pain38. 
Thus attention was drawn on other possible explana-
tions. In another study5 it was proposed that CP pain 
can be provoked by other molecules, like cytokines, 
trypsin, bradykinin along with protons, hydrogen sul-
fide, serotonin and calcium. These agents are respon-
sible for reducing the threshold for peripheral sensory 
nerve fibers’ activation. The key mediator of these 
agents’ upregulation is the damage of acinar cells in 
the inflamed pancreas.
For example bradykinin, a well-known activator 
of sensory neurons can indirectly trigger the transient 
receptor potential vanilloid (TRPV1) by producing 
arachidonic acid metabolites and lipoxygenase prod-
ucts39. TRPV1 is a member of an ion channels super-
family involved in sensory transduction. It is activated 
by a variety of chemical agents (mainly capsaicin), 
acid (protons, H+), heat and mediators (bradykinin, 
substance P, glutamate, prostaglandins and ATP), fac-
tors which lower its activation threshold12. It is ex-
pressed on C and Αδ nerve fibers and it is considered 
a non-selective cation channel permitting the flow of 
cations inwards the cell when activated. As a result, 
neurons depolarize and release neurotransmitters, 
such as substance P (SP) and calcitonin gene-related 
peptide (CGRP) in the spinal cord and the periphery. 
It has been documented that in human CP specimens 
there is an upregulation of SP- and CGRP- immuno-
reactive nerve fibers40. In the pancreas these two noci-
ceptive activation markers contribute to local inflam-
mation by their vasodilatory and chemotactic features. 
SP is mainly vasoconstructive in nature, causing en-
thothelial cell contraction and plasma extravasation. 
However, it has been reported that SP can also act as 
a vasodilator41. CGRP is considered a vasodilator con-
tributing to edema formation. Thus, TRPV1 is said 
to contribute to pancreatic inflammation by provok-
ing vasodilation, and plasma extravasation12. It is also 
considered a mediator of neuronal hypersensitivity 
and an integrator of responses to inflammatory me-
diators. In pathological conditions, a change in the 
expression and sensitivity of the TRPV1 pain chan-
nel leads to chronic pain experienced even after the 
noxious stimulus has disappeared. In a CP study in 
humans an upregulation of TRPV1 receptors in pan-
creatic tissues was found even though no connection 
to pain scores was observed42. 
SP and CGRP seem to be key factors in the so-
called neurogenic inflammation. This is defined as the 
inflammatory process caused by substances released 
from sensory nerves when activated. So, inflamma-
tion process along with hyperexcitabililty of pancre-
atic receptors contribute to the pathogenesis of CP 
pain. Local administration of these two proinflamma-
tory actors can mimick neurogenic inflammation and 
the use of antibodies and antagonists can block this 
phenomenon12. 
SP has also been involved in the direct stimula-
tion of interleukin 8 (IL-8) in macrophages surround-
ing pancreatic nerves. In alcoholic CP an increased 
expression of IL-8 in inflammatory cells has been 
detected. The increased mRNA expression of IL-8 
in CP can be mediated by SP release. By exciting 
post-ganglion sympathetic neurons, IL-8 is capable 
of inducing hyperalgesia. Being itself a proinflamma-
tory cytokine, IL-8 is said to take part in leukocyte 
recruitment and activation. In this sense, IL-8 seems 
to play an important role in the initiation and mainte-
nance of the inflammatory process and chronic pain in 
CP43. CP pain mechanism is also yielded by mast cells 
involved in nociceptive signaling. This hypothesis is 
based on evidence that mast cells have been related 
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to other pathological conditions where pain is a car-
dinal symptom. Mast cells are usually located around 
and within the perineurium of pancreatic nerve fibers. 
Thus they participate in the neuroimmune interaction 
created between neurons and immune cells, another 
proposed CP pain induction process. They also release 
mediators that increase neuronal excitability and pain 
signal transmission. Neurotransmitters (SP) can pro-
voke mast cells degranulation. These products (trypt-
ase and histamine) are thought to contribute to pain 
development by sensitizing and/or activating primary 
afferent neurons in the pancreas. Examining autopsy 
specimens of patients with painful CP, they exhibited 
a 3.5-fold increase in pancreatic mast cells compared 
to those in painless CP patients. In this experimental 
mice model of CP researchers also demonstrated that 
wild-type mice were more sensitive to pain in relation 
with mast cell deficient mice44.
Furthermore, pain mechanism in CP has been re-
lated to the key receptor of SP, neurokinin-1 (NK-1R). 
An upregulation of NK-1R in nerves, fibroblasts and 
inflammatory cells (mostly mononuclear and poly-
nuclear) has been documented. In this study, a cor-
relation between NK-1R expression and features of 
CP pain (intensity and frequency) was established 30. 
NK-1R cited in the epineural nerve layer is thought to 
exert a direct influence on CP pain pathogenesis, since 
it leads to vasoconstriction and ischemia of pancreatic 
nerves45.
One of the initial facts in pancreatitis is the acti-
vation of trypsinogen to trypsin, leading to a proteo-
lytic cascade, the gland’s autodigestion and features 
of inflammation12. Trypsin as a pancreatic protease 
can cause a sensory neuron hypersensitivity, by acting 
on the proteinase-activated receptor 2 (PAR-2), which 
is a pancreas located nociceptive receptor. PAR-2 is 
expressed in acinar cells and ductal epithelium and it 
regulates the gland’s exocrine secretion. Moreover, it 
can be found in endothelial, epithelial, mast cells and 
dorsal root ganglion neurons. It provokes vasodila-
tion in vascular endothelial nerves and helps neuro-
transmission in neurons12. In an experimental model 
of pancreatitis, abdominal hypersensitivity could be 
ameliorated by the administration of proteinase in-
hibitors, thus blocking PAR-2 involved in pain gen-
esis4. The same findings were observed in the study of 
Hoogerwerf et al46. They found that trypsin’s infusion 
resulted in the dorsal root ganglia neurons’ activation 
by binding to PAR-2.
Neurotrophic factors have also been investigated 
regarding their possible role in CP pain pathogenesis. 
The nerve growth factor (NGF) was the first one to be 
implied, since it has been found overexpressed in CP 
tissue samples. It was cited in hypertrophic pancre-
atic nerves, intrapancreatic ganglia, metaplastic ductal 
cells and acinar cells47. NGF is believed to take part in 
neural development involving proliferation, matura-
tion and survival of central and peripheral nerves. It 
has also been involved in the activation of nociceptive 
nerve fibers causing a hyperalgesia state. This is based 
on evidence that there is an interaction between NGF 
and signaling pain systems in adult animals48. NGF 
seems to be a mediator of inflammatory pain states. 
NGF is also thought to mediate the SP and CGRP 
synthesis (by increasing the TRPV1 sensitivity) and 
histamine release thus influencing chronic pain49.It 
can regulate TRPV1 expression either by sensitiz-
ing TRPV1-bearing neurons or by upregulating its de 
novo expression12. 
NGF exerts its role by binding to two types of cell 
surface receptors, the high-affinity receptor tyrosin ki-
nase receptor A (TrkA) and the low-affinity receptor 
p7550. TrkA are located on primary afferent nocicep-
tive neurons. In a study of CP tissue samples it was re-
vealed that NGF mRNA was positively related to the 
degree of fibrosis, acinar cell injury and ductal meta-
plasia. However, no relation was established between 
NGF and pain features. It was TrkA mRNA expres-
sion that was linked to the intensity of pain in CP. This 
study underlines the role of the NGF/TrkA pathway in 
CP pain syndrome and neural morphological changes. 
Immunohistochemistry revealed that enlarged pan-
creatic nerves were the rule and they exhibited strong 
TrkA immunoreactivity. The electron microscope ex-
amination showed that even though pancreatic nerves 
were preserved, they appeared altered in CP. Their 
number and diameter were increased and their peri-
neural sheath was destroyed, thus rendering nerves 
liable to bioactive irritant substances. This neuroim-
mune interaction is responsible for CP pain pathogen-
esis. TrkA was also found overexpressed in the peri-
neurium . Even though the underlying mechanisms of 
nerve changes remain poorly understood, it has been 
assumed that the NGF/TrkA pathway and its activa-
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tion is a key actor. There is growing evidence of the 
NGF/TrkA pathway influence on CP pain syndrome. 
A case of patients sharing insensitivity to painful stim-
uli and loss of sensory neurons due to a mutation in 
the TrkA gene has been reported 51. In animal models 
the use of either anti-NGF antibodies or TrkA-immu-
noglobulin G fusion protein has the capacity of reduc-
ing hyperalgesia4.
Another member of the neurotrophin family relat-
ed with CP pain states is the brain-derived neurotroph-
in factor. It was found that it can promote excitability 
in nociceptive sensory neurons either by linking to the 
p75 receptor or by using the sphingomyelin pathway 
52.Its increased levels in CP and a strong relation with 
pain intensity have been reported in the study of Zhu 
et al53.It is upregulated in degenerating acinar cells, 
enlarged nerves, intrapancreatic ganglia and dorsal 
root ganglia in CP5. It has also been suggested that 
artemin, a member of the glial cell-line derived neu-
rotrophic factor family and its receptor GFRα3 are in-
volved in CP peripheral nociception, since they have 
both been found overexpressed in CP. A correlation 
between artemin and the severity of CP pain (fre-
quency and intensity) was established, since this neu-
rotrophic factor is responsible for thermal hyperalge-
sia and neural growth in the pancreas54. Due to neural 
damage intrapancreatic ganglia and/or Schwann cells 
produce excessive amounts of artemin thus exciting 
dorsal root ganglia neurons. These neurons become 
a source of extrapancreatic artemin which then can 
be transferred to the gland enhancing the local neu-
ral sprouting11 .These findings point towards the ex-
istence of interplay of inflammatory cells, pancreatic 
nociceptive neurons, neuropeptides and their recep-
tors leading to a state of peripheral nociceptive excit-
ability responsible for CP pain sensation.
Peripheral extrapancreatic nociceptive mechanisms
The importance of extrapancreatically located no-
ciceptive mechanisms in the CP pain origin has also 
been emphasized. Evidence of this was provided by 
an experimental animal model of CP55. In that study, 
trinitrobenzene sulfonic acid was administered in rats 
in order to induce CP. More depolarized resting poten-
tials and suppression of A-type potassium current den-
sity were recorded in pancreas-specific DRG neurons 
compared to controls. Furthermore, increased TRPV1 
expression and enhanced capsaicin responsiveness of 
DRG neurons related to pancreas were demonstrated 
in this CP model. This DRG neuronal sensitization is 
said to contribute to pain signals transduction and per-
ception in CP.
Peripheral neuropathic mechanisms
The notion of pancreatic neuropathy as a possible 
pathogenetic mechanism in CP pain was initially hy-
pothesized based on neural alterations in histopatho-
logical tissue samples. Keith et al56 were the first to 
report an infiltration of inflammatory cells, mostly eo-
sinophils around intrapancreatic nerves in CP. An im-
portant correlation of pain scores with eosinophilic in-
filtration was demonstrated in that study. This finding 
was advocated by other studies1,11 showing that nerves 
in CP undergo major changes. Analyzing intrapancre-
atic nerves it was found that they were increased in 
terms of their number / density and they were hyper-
trophic. In addition, a severe neural damage was de-
tected. The perineurium was no longer intact, it was 
disrupted. Thus its role as a protective barrier did not 
exist and inflammatory cells could invade the inner 
part of nerves. There they could secrete noxious fac-
tors or agents. Researchers came to the conclusion 
that pain is not induced by neural constriction due to 
fibrosis and that these neural changes possibly affect 
both sensory and motor nerves11. The term pancreat-
ic neuritis was introduced in order to exemplify the 
phenomenon of neural damage, neural sprouting and 
hypertrophy along with inflammatory cells’ penetra-
tion into pancreatic nerves. Pancreatic neuritis was 
perceived as a responsible factor of CP pain induction.
Years later, more detailed studies57 were the first 
to demonstrate a causal relation between pancreatic 
neuritis and frequency / intensity of CP pain. In this 
way, pancreatic neuropathy and the neuropathic ele-
ment of CP pain were established. Neural intrapancre-
atic damage is followed by a repairing attempt defined 
as pancreatic neuroplasticity. Increased neural density 
and hypertrophy are the major neuroplastic changes 
involved in CP pain initiation and maintenance. A 
well-known neural plasticity marker, the Growth-as-
sociated protein 43 has been found overexpressed in 
CP tissue samples .Neural Growth-associated protein 
43 immunoreactivity was closely linked to CP pain 
scores48.
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Pancreatic neuropathy also results in an altered in-
nervation of the gland in CP. Both sympathetic and 
parasympathetic innervations appear seriously di-
minished especially in patients with abdominal pain 
and pancreatic neuritis. Neural remodeling is anoth-
er feature of the pancreatic neuropathic pain theory 
which may in part explain the reason why denerva-
tion techniques are poorly successful in the CP pain 
treatment. It suggests that since sympathetic nerves 
appear decreased in CP then pain should be trans-
mitted by afferents other than the ones running with 
the splanchnic nerves56. Neural remodeling stands 
for both nerve alterations and glia activation result-
ing in a different type of CP nerve population 11. Glia 
cells of the peripheral nervous system, Schwann cells 
exhibit a proliferation and de-differentiation because 
of the neural injury in CP. By releasing neurotrophic 
factors they sensitize nociceptors and promote axonal 
repair and neural sprouting58. Glial activation is dem-
onstrated by alterations in two markers, the glial tran-
scription factor Sox 10 and the neuroepithelial stem 
cell marker Nestin. In CP there is a down-regulation 
of neural Sox10 expression indicating a decrease of 
mature Schwann cells and a dramatic up-regulation of 
neural Nestin immunoreactivity contributing to neural 
sprouting11.
In an attempt to clarify the way inflammatory cells 
gather into intrapancreatic nerves, it was suggested 
that neuronal chemokines have a role in yielding CP 
pain. The prototype of such molecules is fractalkine59.
It can influence CP neuropathic alterations and pain, 
since it is a chemoattractant for immune cells (granu-
locytes and macrophages), it takes part in glia cells’ 
activation and pancreatic tissue fibrosis. It exerts fi-
brogenic and pain-regulating effects. In the same 
study, an overexpression of tissue fractalkine and its 
receptor CX3CR1 on protein level together with in-
creased nerve immunoreactivity were recorded. Thus 
these two were related to the pathogenesis of visceral 
pain in CP. 
Central neuropathy
The continuous peripheral sensitization of the pan-
creatic nociceptors ends up in spinal neurons’ excit-
ability. This persistent visceral nociceptive input en-
hances the transmission of nociceptive signals to the 
brain by the spinal dorsal horn neurons cited in the 
substantia gelatinosa. Central sensitization is respon-
sible for the two characteristic symptoms of neuro-
pathic pain, that is allodynia (pain sensation caused 
by non-noxious stimuli) and hyperalgesia (increased 
pain sensation triggered by a normal pain stimulus)56. 
Central hyperexcitability becomes clinically obvious 
by the increased area of the referred pain sensation, a 
key element in neuropathic pain. This is due to the fact 
that afferent nerve fibers from different visceral and 
somatic organs seem to converge on the same spinal 
neurons. It is also accompanied by the phenomenon 
of temporal summation. This means that repeated 
pain stimuli tend to become more and more painful 
even though the stimulus’ intensity remains the same. 
Central hyperexcitability also provokes a state of gen-
eralized hyperalgesia56. Different causal mechanisms 
have been proposed for this hyperalgesia state16. One 
possibility is that the ongoing visceral nociceptive 
input results in a supraspinal (rostral ventromedial 
medulla) descending facilitation perpetuating chronic 
pain situation. This was exemplified in the study of 
Vera-Portocarrero et al60 using an experimental rat 
model of CP. Depleting brainstem cells responsible 
for the descending inhibitory control, it was found that 
CP hypersensitivity could be ameliorated. Inhibitory 
control activated in the presence of ongoing nocicep-
tive input seems to be impaired in CP. Pronounced 
hyperalgesia has also been attributed to a state of au-
tonomous central sensitization. In this case, due to the 
enhanced peripheral nociceptive input, central neuro-
plasticity appears. These changes in central pain pro-
cessing make pain perception pathological. 
Central neuroplasticity
Focusing on cerebral pain processing in CP, increased 
cerebral surface activity and altered brain potentials, 
key features of neuropathic pain, have been report-
ed11,16,56. CP patients exhibit an increased theta wave 
activity on electroencephalogram during painful vis-
ceral stimulation. Modified CNS activity is also advo-
cated by the reorganization in cortical projections of 
the nociceptive system because of the recurrent pain 
syndrome in CP. A discrepancy in latency and topo-
graphic distribution exists when CP patients’ brain 
potentials are compared to controls. Analysis of the 
typical viscero-sensory areas of the cerebral cortex 
(the bilateral insula, the anterior cingulated gyrus and 
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the bilateral secondary somatosensory areas) in CP 
patients strongly supports the hypothesis of changes 
in brain pain processing56. An overactivity detected 
in the right secondary somatosensory cortex has been 
attributed to the increased glutamate levels in CP pa-
tients.This increase in glumatamate seems responsible 
for the excitable cortex activity and it can account for 
a pain-sustaining central neuroplasticity. The same 
study provides a link between peripheral and central 
neuropathy in CP. Researchers hypothesized that pain 
mechanisms can either be a maladaptive or salutogen-
ic response to the disease. Pancreatic inflammation 
and neuropathy act as a stimulus for local nociceptive 
nerves. Once they are activated, they transmit visceral 
nociceptive information to the CNS. So, a neural net-
work is activated, generating pain and increasing or 
decreasing the glandular inflammatory process. In this 
sense, a vicious circle of inflammation / pain can be 
created and sustained or pain can be the body’s warn-
ing of pancreatic malfunction.
It could be claimed that pain in CP still remains a 
challenge since its underlying mechanisms are poorly 
understood. A variety of pain-induction mechanisms 
has been proposed and new theories are still evolving. 
Pancreatitis-induced pain is probably multifactorial in 
origin and a network of peripheral and central pro-
cesses is involved. It is hypothesized that the persis-
tent pancreatic inflammation in CP causes a release 
of mediators which sensitize pancreatic nociceptive 
receptors thus they increase in response. The ongoing 
nociceptive input results in plastic changes in the spi-
nal cord and central sensitization. Thus nociceptive in-
formation is transmitted to central pain-related areas, 
the viscero-sensory areas of the cerebral cortex, where 
pain sensation is perceived and further processed. Un-
derstanding the underlying CP pain pathogenesis will 
provide the basis for more effective future medical 
approaches to this refractory chronic condition. It is 
a field needing further exploration, so that CP pain 
management will no longer be unsuccessful, leading 
patients to hospitalizations, medical interventions and 
drug overuse.
ΠΕΡΙΛΗΨΗ Σκοπός της παρούσας εργασίας είναι η βιβλιογραφική ανασκόπηση της χρόνιας παγκρεατίτιδας και των 
βασικών μηχανισμών επαγωγής πόνου. Ορίζεται ως μια χρόνια φλεγμονώδης διαδικασία με καταστροφή ή πλήρη εξάλειψη 
του παρεγχυματικού ιστού και ίνωση. Ένα από τα κυρίαρχα συμπτώματα της χρόνιας πακρεατίτιδας είναι ο πόνος, αμβλύς 
επιγαστρικός που αντανακλά στην πλάτη, επαναλαμβανόμενος ή συνεχής. Αναφέρεται σε μια δυσάρεστη, ενοχλητική αίσθηση 
που παράγεται από ένα ερέθισμα όπως φλεγμονή και βλαπτικούς παράγοντες. Μια αντίδραση του ανθρωπίνου σώματος, 
που προειδοποιεί για την παρουσία ενδογενούς ή εξωγενούς κινδύνου. Στην περίπτωση του χρόνιου παγκρεατικού πόνου, 
ένας μεγάλος αριθμός αιτιολογικών μηχανισμών έχει προταθεί. Παλαιότερα, επικρατούσε η αντίληψη ότι προέρχεται από τη 
φλεγμονώδη διαδικασία και την ίνωση. Η παγκρεατική ισχαιμία σε σχέση με την αυξημένη πίεση παρεγχυματικού ιστού και 
πόρων και εξωπαγκρεατικές αιτίες όπως η στένωση του χοληδόχου πόρου και του δωδεκαδακτύλου έχουν επίσης προταθεί. 
Πρόσφατα, έμφαση έχει δοθεί στο νευροπαθητικό στοιχείο όπου ο πόνος προκαλείται από περιφερικούς μηχανισμούς 
αλγαισθησίας. Η παγκρεατική νευροπάθεια, η αυξημένη πυκνότητα νευρικών ινών και η υπερτροφία μαζί με κεντρική 
ευαισθητοποίηση (υπερδιέγερση νωτιαίου μυελού και εγκεφάλου) συμμετέχουν επίσης σε αυτή τη θεωρία. Οι διάφορες 
υποθέσεις για τον μηχανισμό επαγωγής του χρόνιου παγκρεατικού πόνου υπογραμμίζουν την πολυπαραγοντικότητά του και 
την ανάγκη για περαιτέρω διερεύνηση.
Λέξεις Κλειδιά: Παγκρεατίτιδα, Χρόνιος πόνος, Νευροπάθεια, Αλγαισθησία.
Μηχανισμοί πόνου στην χρόνια παγκρεατίτιδα.
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